Azithromycin versus standard care in patients with mild-to-moderate COVID-19 (ATOMIC2): an open-label, randomised trial
Hinks et al., The Lancet Respiratory Medicine, doi:10.1016/S2213-2600(21)00263-0
https://c19early.org/hinksaz.html